Acadia Pharmaceuticals 2025 Q3 Earnings Beats Expectations with 11.3% Revenue Growth and 119.1% Net Income Surge

Acadia Pharmaceuticals (ACAD) reported fiscal 2025 Q3 earnings on November 5, 2025, exceeding expectations with 11.3% year-over-year revenue growth and a record net income of $71.78 million. The company raised its 2025 guidance, reflecting strong performance in key products and robust commercial execution.

Revenue

Total revenue surged to $278.63 million in Q3 2025, up from $250.40 million in the prior year, driven by 11.3% growth. Product sales, net, accounted for the entirety of total revenue, with NUPLAZID and DAYBUE contributing $177.5 million and $101.1 million, respectively. This performance underscores the company’s ability to capitalize on demand for its CNS and rare disease treatments.

Earnings/Net Income

Acadia’s EPS soared 115% to $0.43 in Q3 2025, compared to $0.20 in 2024 Q3, while net income jumped 119.1% to $71.78 million. The company achieved its highest net income in over two decades, driven by strong sales execution and favorable tax benefits. The performance exceeded expectations, with a significant EPS increase and record net income.

Post-Earnings Price Action Review

The stock edged up 2.62% during the latest trading day but declined 0.89% for the week, while gaining 3.43% month-to-date. This mixed short-term volatility aligns with the company’s guidance updates and management’s optimism about 2025 sales targets.

CEO Commentary

CEO Catherine Owen Adams highlighted “another strong quarter” with $278.6 million in total revenues, including record NUPLAZID sales of $177.5 million and DAYBUE sales of $101.1 million. Adams emphasized confidence in achieving $1 billion in 2025 sales, citing momentum in commercial operations and pipeline advancements like Phase 2/3 trials for ACP-204 and trofinetide.

Guidance

Acadia raised 2025 revenue guidance to $1.070–$1.095 billion, up from $1.045–$1.095 billion, with NUPLAZID net sales projected at $685–$695 million and DAYBUE at $385–$400 million. R&D expenses are expected to range from $335–$345 million, and SG&A from $540–$555 million. The updated guidance now includes international patient programs, previously excluded.

Additional News

Recent developments include institutional investor activity, with American Century Companies and Vanguard Group significantly increasing stakes in ACAD. Burney Co. reduced its holdings by 71.4% in Q2 2025, while Nuveen LLC and Jacobs Levy Equity Management boosted their positions. Additionally, Acadia appointed Konstantina Katcheves as Chief Business and Strategy Officer, signaling a strategic shift toward global partnerships. The company also initiated a Phase 2 trial for ACP-204 in Lewy Body Dementia Psychosis and a Phase 3 trial for trofinetide in Japan. These moves underscore Acadia’s focus on expanding its pipeline and leveraging business development opportunities.

Conclusion

Acadia’s Q3 results highlight its leadership in rare disease innovation, with robust revenue growth, record net income, and updated guidance reflecting confidence in future performance. The company’s strategic investments in R&D and commercial expansion position it to capitalize on long-term opportunities in the biopharmaceutical sector.